Effects of pentoxifylline on pulmonary function and results of cytologic examination of bronchoalveolar lavage fluid in horses with recurrent airway obstruction

American Journal of Veterinary Research

Volumn 63, Issue 3, 2002, Pages 459-463

  Léguillette, Renaud ^a   Désévaux, Cyril ^a   Lavoie, Jean Pierre ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; DRUG VEHICLE; PENTOXIFYLLINE; UNCLASSIFIED DRUG;

AIRWAY OBSTRUCTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORN SYRUP; CYTOPATHOLOGY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HORSE; LUNG COMPLIANCE; LUNG FUNCTION; LUNG LAVAGE; LUNG RESISTANCE; MALE; NONHUMAN; RECURRENT DISEASE;

ANIMALIA; EQUIDAE; EQUUS CABALLUS; ZEA MAYS;

EID: 0036521395     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.459     Document Type: Article

References (39)

1. Robinson NE, Derksen FJ, Olszewski MA, et al. The pathogenesis of chronic obstructive pulmonary disease of horses. Br Vet J 1995;152:283-306.
2. Lavoie JP. Chronic obstructive pulmonary disease. In: Robinson NE, ed. Current therapy in equine medicine. 4th ed. Philadelphia: WB Saunders Co, 1997;431-435.
3. Cortijo J, Bou J, Beleta J, et al. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 1993;108:562-568.
4. Pearson EG, Riebold TW. Comparison of bronchodilators in alleviating clinical signs in horses with chronic obstructive pulmonary disease. J Am Vet Med Assoc 1989;194:1287-1291.
5. Han J, Thompson P, Bender B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990 172:391-394.
6. van Furth AM, Steenwijk TM, Langermans JA, et al. In vitro effect of dexamethasone, pentoxifylline, and anti-endotoxin monoclonal antibody on the release of proinflammatory mediators by human leukocytes stimulated with Haemophilus influenzae type B. Pediatr Res 1994;35:725-728.
7. van Furth AM, Seijmonsbergen EM, Langermans JA, et al. Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor alpha, interleukin-1 beta (IL-1 beta), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995;2:689-692.
8. Chen YL, Le Vraux V, Giroud J, et al. Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur J Pharmacol 1994;271:319-327.
9. Louie A, Baltch AL, Franke MA, et al. Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumor necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone. J Antimicrob Chemother 1994;34:975-987.
10. Milam SB, Mackay RJ, Skelley LA. Secretion of tumor necrosis factor by endotoxin-treated equine mammary exudate macrophages: effect of dexamethasone and pentoxifylline. Cornell Vet 1992;82:435-446.
11. Boogaerts MA, Malbrain S, Meeus P, et al. In vitro modulation of normal and diseased human neutrophil function by pentoxifylline. Blut 1990;61:60-65.
12. Stellin GP, Waxman K. Current and potential effects of pentoxifylline. Compr Ther 1989;15:11-13.
13. Samlaska CP, Winfield EA. Pentoxifylline-clinical review. J Am Acad Dermatol 1994;30:603-621.
14. Neuner P, Klosner G, Schauer E, et al. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994;83:262-267.
15. Oka Y, Murata A, Nishijima J, et al. Inhibitory effect of pentoxifylline and prostaglandin E1 on the release of neutrophil elastase from FMLP-stimulated neutrophils. J Med 1991;22:371-382.
16. Currie MS, Rao KM, Padmanabhan J, et al. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990;47:244-250.
17. Lapointe JM, Lavoie JP, Vrins A. Effects of triamcinolone acetonide on pulmonary function and bronchoalveolar lavage cytologic features in horses with chronic obstructive pulmonary disease. Am J Vet Res 1993;54:1310-1316.
18. Hawkins ES, Ribeiro HA. Pentoxifylline review. J Am Podiatr Med Assoc 1987;77:645-647.
19. Zabel P, Entzian P, Dalhoff K, et al. Pentoxifylline in the treatment of sarcoidosis. Am J Respir Crit Care Med 1997;155:1665-1669.
20. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline: an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995;22:595-599.
21. Weiss DJ, Evanson OA, Geor RJ. The effects of furosemide and pentoxifylline on the flow properties of equine erythrocytes: in vitro studies. Vet Res Commun 1994;18:373-381.
22. Geor RJ, Weiss DJ, Burris SM, et al. Effects of furosemide and pentoxifylline on blood flow properties in horses. Am J Vet Res 1992;53:2043-2049.
23. Barton MH, Moore JN. Pentoxifylline inhibits mediator synthesis in an equine in vitro whole blood model of endotoxemia. Circ Shock 1994;44:216-220.
24. Barton MH, Moore JN, Norton N. Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin. Am J Vet Res 1997;58:1300-1307.
25. Barton MH, Ferguson D, Davis PJ, et al. The effects of pentoxifylline infusion on plasma 6-keto-prostaglandin F1 alpha and ex vivo endotoxin-induced tumour necrosis factor activity in horses. J Vet Pharmacol Ther 1997;20:487-492.
26. Baskett A, Barton MH, Norton N, et al. Effect of pentoxifylline, flunixin meglumine, and their combination on a model of endotoxemia in horses. Am J Vet Res 1997;58:1291-1299.
27. Nolte D. Pulmonary function tests on the bronchospasmolytic effect of 3,7-dimethyl-1-(5-oxo-hexyl)-xanthine. Arzneimittellforschung 1971;21:1453-1456.
28. Jean D, Vrins A, Lavoie JP. Monthly, daily, and circadian variations of measurements of pulmonary mechanics in horses with chronic obstructive pulmonary disease. Am J Vet Res 1999;60:1341-1346.
29. Crisman MV, Wilcke JR, Correll LS, et al. Pharmacokinetic disposition of intravenous and oral pentoxifylline in horses. J Vet Pharmacol Ther 1993;16:23-31.
30. Weiss DJ, Geor RJ, Burris SM, et al. Effects of pentoxifylline on equine neutrophil function and flow properties. Can J Vet Res 1992;56:313-317.
31. Sullivan GW, Carper HT, Novick WJJ, et al. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988; 56:1722-1729.
32. Essais pharmacologiques de la pentoxifylline chez le cheval. Victoriaville, QC, Canada: Rhone-Mérieux Canada, 1994;110-115.
33. Smith RV, Waller ES, Doluisio JT, et al. Pharmacokinetics of orally administered pentoxifylline in humans. J Pharm Sci 1986;75:47-52.
34. Entzian P, Bitter-Suermann S, Burdon D, et al. Differences in the anti-inflammatory effects of theophylline and pentoxifylline: important for the development of asthma therapy? Allergy 1998; 53:749-754.
35. Grunig G, Hermann M, Howald B, et al. Partial divergence between airway inflammation and clinical signs in equine chronic pulmonary disease. Equine Vet J 1989;21:145-148.
36. Watson ED, Sweeney CR, Steensma KA. Arachidonate metabolites in bronchoalveolar lavage fluid from horses with and without COPD. Equine Vet J 1992;24:379-381.
37. Franchini M, Gilli U, Akens MK, et al. The role of neutrophil chemotactic cytokines in the pathogenesis of equine chronic obstructive pulmonary disease (COPD). Vet Immunol Immunopathol 1998;66:53-65.
38. Naureckas ET, Factor P, Benjaminov O, et al. Pentoxifylline does not protect against hyperoxic lung injury in rats. Eur Respir J 1994;7:1397-1402.
39. Elferink JG, Huizinga TW, de Koster BM. The effect of pentoxifylline on human neutrophil migration: a possible role for cyclic nucleotides. Biochem Pharmacol 1997;54:475-480.